April 2012 Briefing - Nephrology
Here are what the editors at HealthDay consider to be the most important developments in Nephrology for April 2012. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Afinitor Approval Expanded to Include Benign Kidney Tumors
FRIDAY, April 27 (HealthDay News) -- Afinitor (everolimus) is the first drug to be approved by the U.S. Food and Drug Administration to treat benign kidney tumors among people with tuberous sclerosis complex (TSC), the agency said in a news release.
Pathway Involved in Kidney Stone Formation Identified
TUESDAY, April 24 (HealthDay News) -- A gene previously linked to an increased risk of developing kidney stones is part of a calcium-sensitive pathway that regulates calcium absorption in the kidney, according to a study in the April 18 issue of The EMBO Journal.
New Fibrate Use Ups Serum Creatinine Levels in Elderly
TUESDAY, April 17 (HealthDay News) -- For elderly adults, new fibric acid derivative (fibrate) use is associated with an increase in serum creatinine levels, in hospitalizations for these levels, and in nephrologist consultations, according to a study published in the April 17 issue of the Annals of Internal Medicine.
Evidence Lacking for Value of CKD Screening and Monitoring
TUESDAY, April 17 (HealthDay News) -- There is no evidence that screening and monitoring for chronic kidney disease (CKD) improves clinical outcomes, according to research published in the April 17 issue of the Annals of Internal Medicine.
Herbal Carcinogen Linked to Urothelial Cancer in Taiwan
FRIDAY, April 13 (HealthDay News) -- A carcinogen produced by Aristolochia plants, which are commonly used in herbal remedies in Taiwan, is associated with signature types of DNA damage linked to aristolochic acid in Taiwanese patients with urothelial carcinoma of the upper urinary tract (UUC), according to a study published online April 9 in the Proceedings of the National Academy of Sciences.
Tivozanib Exhibits Antitumor Activity in Renal Cancer
TUESDAY, April 10 (HealthDay News) -- The potent, selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, tivozanib, demonstrates antitumor activity and is well tolerated in patients with advanced/metastatic renal cell carcinoma (RCC), according to research published online April 9 in the Journal of Clinical Oncology.
Medical Malpractice Claims Incur Substantial Defense Costs
WEDNESDAY, April 4 (HealthDay News) -- Defense costs for medical malpractice claims vary among specialties and are higher for claims that result in indemnity payments, according to a letter published in the April 5 issue of the New England Journal of Medicine.